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Summary  
The maternal Tdap (tetanus, diphtheria and acellular pertussis) vaccination program in the UK has 
successfully reduced cases of pertussis in young infants. In addition to prevention of pertussis cases, 
it is also important to investigate persistence of maternal antibody during infancy and possible 
interference of maternal antibodies with infant responses to vaccines. We recruited mother-infant 
pairs from vaccinated and unvaccinated pregnancies and measured concentrations of IgG against 
pertussis toxin (PTx), filamentous hemagglutinin (FHA), pertactin (Prn), diphtheria toxin (DTx), 
tetanus toxoid (TTx) Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae in mothers 
and infants at birth, and in infants at 7 weeks and at 5 months. 31 mother-infant pairs were tested. 
Tdap-vaccinated women had significantly higher antibody against Tdap antigens, compared to 
unvaccinated women (DTx p=0.01; PTx, FHA, Prn and TTx p<0.001). All antibodies were actively 
transferred to the infants (transfer ratio >1) with higher transfer of DTx (P=0.04) and TTx (P=0.02) 
antibody in Tdap-vaccinated pregnancies compared to unvaccinated. Infants from Tdap-vaccinated 
pregnancies had significantly elevated antibodies to all antigens at birth (p<0.001) and at 7 weeks 
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(FHA, Prn, TTx p<0.001; DTx p=0.01; PTx p=0.004) compared to infants from unvaccinated 
pregnancies. Infants from Tdap-vaccinated and unvaccinated pregnancies had comparable antibody 
concentrations following primary pertussis immunization (PTx p=0.77; FHA p=0.58; Prn p=0.60; DTx 
p=0.09; TTx p=0.88). These results support maternal immunisation as a method of protecting 
vulnerable infants during their first weeks of life.  
 
Introduction 
Pertussis is a highly contagious infection of the upper respiratory tract primarily caused by the 
bacterium Bordetella pertussis.1 Although pertussis affects all age groups, complications and 
mortality from infection are highest in infants too young to be fully immunised. The resurgence of 
pertussis in vaccinated populations has caused many infant deaths, resulting in a major worldwide 
public health concern.2 Following 14 infant deaths in the UK in 2012, a nationwide pertussis 
vaccination programme for pregnant women was introduced.3 The rationale of maternal vaccination 
is to boost the observed low pertussis antibody levels in the pregnant population,4 thereby 
increasing levels of antibody transferred to the fetus in utero. The program in the UK is safe5 and 
highly effective,6 with the highest proportional reduction in cases and hospital admissions in infants 
less than three months of age.7 Maternal pertussis vaccination has been introduced by the United 
States, Australia, South American and other European countries.8–10 
Following acellular pertussis vaccination during pregnancy, antibody concentrations in cord blood to 
vaccine antigens, including pertussis toxin (PTx), filamentous haemagglutinin (FHA) and pertactin 
(Prn), are increased in the infant, and to concentrations greater than or equal to those in the 
mother,11 presumably due to active transport of antibodies across the placenta.12 Associations 
between high maternal antibody levels in the infant and subsequent impaired vaccine responses 
have been observed for influenza and measles,13,14 and recent studies have suggested maternal 
pertussis vaccination may be associated with blunted infant responses to primary immunisation.15–18 
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Since the introduction of the program, no UK study has investigated vaccine responses in mother-
infant pairs from vaccinated pregnancies, compared to unvaccinated controls collected over the 
same time-period. Our study thus aimed to determine the impact of maternal pertussis vaccination 
on infant antibody responses to primary immunisation with acellular pertussis, Haemophilus 
influenzae type b (Hib) and Streptococcus pneumoniae conjugate polysaccharide vaccines.  
 
Materials and Methods 
Study subjects 
Women with singleton, uncomplicated term pregnancies booked for maternity care at Imperial 
College Healthcare NHS Trust were recruited antenatally. Exclusion criteria included maternal 
autoimmune disease, hypertension, diabetes and pregnancy pathologies. Randomisation into 
vaccinated and unvaccinated groups was not possible for ethical reasons, as the maternal pertussis 
vaccination programme was in place at the start of the study. The recruits gave birth between May 
2014 and September 2016 inclusive. The study was approved by Research Ethics Committee 
(13/LO/1712) and written informed consent was obtained.  
 
Serum Collection 
Maternal serum was routinely collected at time of booking for antenatal care, from the cord 
immediately at birth and from women postnatally within 72h of delivery. Serum was collected from 
infants at seven weeks (one week prior to commencing primary immunisations) and five months of 
age (one month after completion of primary immunisations). Maternal blood collected at the time of 
booking for antenatal care was taken into Vacutainer® Plastic SSTTM II Advance tubes (Becton 
Dickinson) and stored samples were obtained following patient consent. All other samples were 
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taken into Z Serum Sep Clot Activator tubes (Greiner Bio-One, UK) and processed by the study team. 
Samples were left for a minimum of 30 minutes prior to centrifugation at 1900g for 10 minutes. 
Maternal and cord blood were processed within 48h of collection and infant blood within 1h of 
collection. All serum aliquots were stored at -80°C prior to further analysis.  
 
Vaccines  
In line with UK vaccine policy, vaccinated women received tetanus, diphtheria and pertussis-
containing vaccines (Tdap); Repevax® (Sanofi Pasteur, France; prior to July 2014) or Boostrix-IPV® 
(GlaxoSmithKline, Belgium; after July 2014). As per routine vaccination schedules in the UK, infants 
received three doses of tetanus, diphtheria and pertussis-containing vaccine at 8, 12 and 16 weeks; 
DTaP5-IPV-Hib (Pediacel®, Sanofi Pasteur, France) or DTaP3-IPV-Hib (Infanrix-IPV-Hib®, 
GlaxoSmithKline, Belgium). All infants received two doses of thirteen-valent conjugate 
pneumococcal polysaccharide vaccine, Prevenar13® (Pfizer, Belgium), at 8 and 16 weeks.  
 
Antibody measurement by Multiplex Immunoassay  
A multiplex immunoassay (MIA) was employed to measure antibody concentrations against 
pertussis, diphtheria, tetanus, pneumococcal and Hib vaccine antigens at the Centre for Infectious 
Disease Control, National Institute of Public Health and the Environment (RIVM), the Netherlands. 
This assay utilises antigen-conjugated microspheres to quantify IgG antibodies using Luminex xMAP 
technology. Three separate assays were performed as previously described to measure antibody 
against: 1) protein antigens PT, FHA, Prn, DT and TT19, 2) pneumococcal polysaccharide antigens 1, 4, 
5, 6B, 7F, 9V, 14, 18C, 19F and 23F20, and 3) the Hib polysaccharide antigen.21 In brief, standard, 
control and serum samples were mixed with microspheres conjugated to vaccine antigen proteins, 
and incubated for 30-45 minutes. R-Phycoerythrin conjugated goat anti-human IgG (Jackson 
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ImmunoResearch Laboratories Inc., Westgrove, PA) was added to detect bound antibodies. Samples 
were processed using a Bio-Plex 200, and results analysed with Bio-Plex Manager software version 
6.1 (Bio-Rad Laboratories, Hercules, CA).  
 
Statistical Analysis 
The primary endpoints of the study were the determination of antibody levels to pertussis and 
pneumococcal vaccine antigens at the five study timepoints, stratified by immunisation status in 
pregnancy. Based on previous antibody studies in pregnant women at a single time point and 
assuming 95% protection in vaccinated women and normal distribution of concentrations between 
the two groups of women, a sample size of 23 per group would theoretically be sufficient to show a 
significant difference between vaccinated and unvaccinated women with a power of 90%, using a 2-
sided test with a significance level of <0.05.  
Results below the limit of detection were assigned the lower limit of quantification: 1IU/ml for PT, 
FHA and Prn; 0.001 IU/ml for DT and TT; 0.01µg/ml for Hib and all pneumococcal polysaccharide 
antigens. Appropriate parametric/non-parametric tests were used following testing for Gaussian 
distribution using D’Agostino–Pearson omnibus normality test. Distribution of measures and effects 
of potential outlying values were examined.22 Outcomes symmetrised by log transformation were 
analysed using mixed-effects linear regression with a random intercept at the participant level 
(mixed command in Stata). Chi-square tests or t-tests identified baseline characteristics for which 
the treatment group was not balanced. We estimated the effect of vaccination on antibody 
concentrations via interactions between the treatment group and time, adjusting variables for which 
groups were not balanced at baseline or follow-up. Marginalisation was used to present group 
differences of each time-point (by use of the contrast and margins post-estimation commands in 
Stata). Results were adjusted for gestation at delivery. Comparisons of longitudinal antibody 
concentrations and the effect of gestation at time of maternal vaccination were performed using 
Stata v.15.  
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The proportion of infant samples with DTx and TTx antibody of  ≥0.1 IU/mL for were calculated,23   
and with PTx, FHA and Prn antibody concentrations ≥20IU/ml.24 Comparisons of transfer ratios and 
antibody half-life between vaccinated and unvaccinated groups were made using the Mann-Whitney 
U-test in GraphPad Prism 7. P values less than 0.05 were considered significant.  
 
Results  
Study population demographics 
We included a total of 150 serum samples, collected from 31 mother-infant pairs with 16 obtained 
from Tdap-vaccinated pregnancies and 15 from unvaccinated pregnancies. At the five-month time 
point, five samples could not be obtained in the unvaccinated group, as mothers withdrew consent 
for further sampling. Detailed clinical data and a study flow diagram are shown in Supplementary 
Table 1 and Supplementary Figure 1, respectively. There were no significant demographic 
differences between vaccinated and unvaccinated mother-infant pairs apart from higher parity in 
unvaccinated mothers, which was corrected for in the analyses. 
 
Robust maternal antibody responses to Tdap booster vaccination in pregnancy  
At the time of delivery vaccinated women had significantly higher antibodies against all Tdap vaccine 
antigens (PTx 3.45 IU/ml; FHA 4.55 IU/ml; Prn 5.86 IU/ml; DTx 0.60 IU/ml; TTx 1.59 IU/ml), than 
unvaccinated mothers (PTx 2.01 IU/ml, p<0.001; FHA 2.31 IU/ml, p<0.001; Prn 1.66 IU/ml, p<0.001; 
DTx 0.19 IU/ml, p=0.01; TTx 0.63 IU/ml, p<0.001) (Figure 1, raw data Supplementary Table 2). 
Women in the Tdap-vaccinated group had higher TTx antibody at baseline, prior to vaccination, (1.06 
IU/ml), than those who were not vaccinated (0.63 IU/ml; p=0.02), which was controlled for in the 
analysis. 
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Maternal vaccination is associated with elevated transplacental anti-DTx and -TTx antibody 
transfer  
Ratios between cord and maternal antibody levels at time of delivery were calculated to measure 
transplacental antibody transfer. There was positive transport of antibody to the infant for all Tdap 
vaccine antigens, independent of vaccination status (Table 1). The transplacental transfer of DTx 
(2.10 IU/ml) and TTx (2.07 IU/ml) was significantly higher in vaccinated groups compared to 
unvaccinated groups (DTx 1.64 IU/ml, p=0.04; TTx 1.58 IU/ml, p=0.02). 
 
Elevated vaccine-specific antibodies in infants in the first seven weeks of life after vaccination 
during pregnancy 
Infant blood was collected at birth and seven weeks, prior to commencement of primary 
immunisation. Infants born to vaccinated mothers had significantly higher antibody against all Tdap 
vaccine antigens at birth (PTx 4.15 IU/ml; FHA 5.27 IU/ml; Prn 6.60 IU/ml; DTx 0.90 IU/ml; TTx 2.15 
IU/ml), than infants from unvaccinated mothers (PTx 2.50 IU/ml; FHA 3.03 IU/ml; Prn 2.24 IU/ml,; 
DTx 0.26 IU/ml; TTx 0.80 IU/ml; all p<0.001) (Figure 1).  
At seven weeks (Figure 1), infants from vaccinated pregnancies had significantly elevated anti-PTx 
(3.15 IU/ml), FHA (4.27 IU/ml), Prn (5.77 IU/ml), DTx (0.38 IU/ml) and TTx (1.28 IU/ml) antibodies 
compared to infants from unvaccinated pregnancies (PTx 1.88 IU/ml, p=0.004; FHA 1.71 IU/ml, 
p<0.001; Prn 1.27 IU/ml, p<0.001; DTx 0.10 IU/ml, p=0.01; TTx 0.31 IU/ml, p<0.001). Maternal 
vaccination had no effect on the half-life of any of the Tdap antibodies (Table 2).  
The percentage of infants reaching protective levels of DTx and TTx antibody (≥0.1 IU/ml) was 
calculated based on defined thresholds. Based on other published literature, the percentage of 
infants reaching an arbitrary threshold of ≥20IU/ml was reported for the pertussis antigens, as there 
is no known correlate of protection. At birth and seven weeks, a significantly higher proportion of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
infants from Tdap-vaccinated pregnancies had PTx, FHA and Prn antibody ≥20IU/ml, and were 
seroprotected for DTx (≥0.1 IU/ml), compared to unvaccinated pregnancies (Figure 1). There was no 
difference in the proportion of infants that were seroprotected for TTx antibody from vaccinated 
and unvaccinated pregnancies at any timepoint. 
 
Impact of maternal Tdap vaccination on the infant response to primary pertussis vaccination 
To determine the impact of maternal Tdap vaccination on infant responses to pertussis vaccination, 
blood was collected one month after completing their primary course of DTaP-IPV-Hib vaccine (8, 12, 
16 weeks). No differences were observed in antibody concentrations, nor the percentage of infants 
reaching defined thresholds to any DTaP vaccine antigens, between infants from vaccinated and 
unvaccinated pregnancies (Figure 1). There were no correlations between the concentrations of 
antibody at birth and in infants post-primary immunisation, in vaccinated nor unvaccinated groups 
(data not shown).  
 
Impact of maternal Tdap vaccination on pneumococcal and Hib antibody levels in infants 
In addition to pediatric DTaP vaccine, potential effects of maternal Tdap vaccination on other 
vaccines in the primary vaccination schedule were investigated for Hib and pneumococcal 
polysaccharide serotypes (ST) 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Pneumococcal and Hib 
antibody concentrations in seven week-old infants did not differ between infants from vaccinated 
and unvaccinated pregnancies (Figure 2). One month after primary PCV13 vaccinations (8, 16 
weeks), infants from unvaccinated pregnancies had significantly higher antibodies against ST7F (2.28 
IU/ml, p=0.002), whereas ST14 was increased in infants from vaccinated pregnancies (1.34 p=0.004, 
p=0.044) (Figure 2, raw data Supplementary Table 2). There were no significant differences in 
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antibody to all other antigens between infants born to Tdap vaccinated and unvaccinated mothers, 
including Hib.  
 
Discussion 
Although the maternal pertussis vaccination program in the UK has successfully reduced cases of 
pertussis in young infants,6,7 it is important to determine if increased maternal pertussis antibody in 
infants is associated with blunted responses to pediatric vaccines. Given that vaccine interference by 
maternal antibody has been shown for vaccines such as measles, we determined anti-pertussis, 
diphtheria, tetanus, Hib and pneumococcal antibody levels in a prospective cohort of maternally-
vaccinated and -unvaccinated mother-infant pairs. In our small study population we found that 
maternal Tdap-vaccination results in robust antibody concentrations in mothers and importantly, in 
their infants during the critical first weeks of life. With this sample size, we did not detect any 
significant impact of maternal Tdap vaccination on infant responses to primary pertussis vaccination. 
We observed active transplacental transfer of maternal antibodies in Tdap-vaccinated and -
unvaccinated groups, as reported by previous studies.15,16,18,28 High levels of maternal antibody have 
been linked to reduced transfer ratios, potentially due to saturation of the neonatal Fc receptor 
(FcRn) for IgG in placenta.29 We observed no such association, and conversely, transfer of DTx and 
TTx antibodies were significantly higher in Tdap-vaccinated pregnancies compared to unvaccinated 
pregnancies, suggesting that the FcRn is not saturated by the IgG levels induced by maternal 
vaccination. Maternal antibody in the infant wanes with time, with varying rates reported.15,30 We 
report a half-life of between 25 and 29.7 days, depending on the antigen. Importantly, the half-life 
of the antibody from vaccinated pregnancies is the same as that from unvaccinated pregnancies, 
meaning that antibody induced by vaccination in pregnancy is just as long-lasting as antibody that is 
present in the mother from previous exposure/vaccination. 
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Between birth to seven weeks, infants from vaccinated pregnancies had significantly higher 
concentrations of antibodies against all acellular pertussis antigens. We used published cut-offs for 
tetanus and diphtheria to define protective antibody concentrations.23 No correlate of protection 
has been defined for pertussis,1 however, high antibody levels are important.31,32 Several papers 
have used arbitrary thresholds when analysing pertussis antibody levels,24,33,34 and for our analysis, 
we set an arbitrary threshold of ≥20IU/ml for PTx, FHA and Prn antibody concentrations. A 
significantly higher percentage of infants from vaccinated pregnancies reached these antibody levels 
for tetanus and diphtheria, and the arbitrarily defined threshold for pertussis antibody in the first 
seven weeks of life, compared to infants born from unvaccinated mothers.  
Following primary immunisation, no differences were observed in concentrations of pertussis 
antibodies between infants from vaccinated and unvaccinated pregnancies. Although it appears 
there is a downward trend in infant FHA, Prn, DTx and TTx antibody levels in the vaccinated group 
between the seven week and five month timepoints, it is important to note that the seven week 
timepoint is essentially a measurement of maternal antibody in infants. As shown by our data, we 
would expect higher levels of maternal antibody in infants whose mothers were vaccinated during 
pregnancy. Unlike in the mothers, it is not possible to compare the pre- and post-vaccination 
antibody levels in infants to measure their response to pertussis vaccination because of the presence 
of maternal antibody at the seven week timepoint.  
In contrast to our findings, a previous larger study in Belgium found that infants from vaccinated 
pregnancies had lower concentrations of PTx and DTx antibodies following primary immunisation, 
compared to infants from unvaccinated mothers.15 Lower DTx and Prn antibodies have also been 
observed in infants from Tdap-vaccinated mothers in Vietnam, compared to a control group whose 
mothers received a tetanus vaccine during pregnancy.16 The difference between our study and 
previous studies could simply be due to our limited sample size but also due to women’s vaccination 
histories, maternal/pediatric vaccine formulations and in the case of the Vietnamese study, different 
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epidemiological backgrounds including natural exposure to B. pertussis. In the only other study in 
the UK, infants from vaccinated pregnancies have previously been shown to have lower PTx, FHA 
and fimbriae 2/3 antibodies after DTaP vaccination, compared to infants from unvaccinated 
pregnancies.17 However, the unvaccinated control group in this study was a historical set of infant 
samples collected 10 months prior the introduction of the maternal vaccination program in response 
to the pertussis outbreak. Thus, these groups could have different confounders, including pertussis 
exposure, particularly as pertussis prevalence is seasonal.1 In contrast, our study collected samples 
from vaccinated and unvaccinated pregnancies over the same time-period.  
Pertussis vaccination during pregnancy has been associated with reduced infant responses to other 
vaccines, such as pneumococcal vaccination17,35. We did not observe any differences in the response 
to Hib vaccination. We also saw very few differences in the concentration of serotype-specific anti-
pneumococcal antibody between groups; five-month old infants from unvaccinated pregnancies had 
elevated ST7F antibody compared to vaccinated pregnancies, and conversely, vaccinated infants had 
elevated ST14.  However, if we perform Bonferonni correction for the ten serotypes that were 
measured, the 0.05 p value cut off is 0.005, which the ST7F and ST14 differences do not reach. In 
contrast to our findings, Ladhani et al.17 and Maertens et al.35 observed blunting of multiple 
pneumococcal serotypes in infants from Tdap vaccinated pregnancies. The blunting of 
pneumococcal responses was largely removed following a booster vaccination at 12 months of age.35 
The reason for the differences between our findings and these studies is not clear, but could be due 
to our small sample size; continued monitoring of the impact of pertussis vaccination during 
pregnancy on infant responses to other vaccines is required.  
Antibodies produced following acellular vaccination wane rapidly.36 The dynamics of the maternal 
anti-pertussis antibody response to vaccination and the efficiency of transplacental antibody 
transfer rates across gestation need to be considered. In 2016, health authorities in the UK 
recommended that maternal pertussis vaccination should be provided earlier in pregnancy, between 
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16-32 weeks gestation, partly based on evidence that vaccination in early second trimester (13-25 
weeks) resulted in higher cord blood antibody levels than third trimester vaccination (≥26 weeks)27. 
Earlier vaccination is now also recommended in Ireland, Argentina and Mexico, among others. The 
extended vaccination window also enables women to be immunised at the time of the 20 week fetal 
anomaly scan, potentially increasing the opportunity to administer the vaccine. An additional 
consideration is preterm birth, which affects 8.6% of births in developed countries.37 Earlier 
vaccination could also protect these preterm infants.38  We were not able to investigate how the 
timing of pertussis vaccination impacts on antibody levels. Future studies should analyse the impact 
of timing of pertussis vaccination during pregnancy and monitor antibody levels between 
pregnancies to determine whether pertussis vaccination is required with each pregnancy, regardless 
of the time between pregnancies. 
The main limitation of the data presented here is the small number of women and infants with 
paired samples included: only a small proportion of women agree to come back for infant follow-up 
in observational cohort studies with little tangible benefit for healthy babies. Therefore, our inability 
to detect potential blunting in vaccine responses in infants born to vaccinated mother could simply 
be due to lack of power. We estimated 95% confidence intervals of the effect sizes using 
bootstrapping, to determine the degree of uncertainty around our estimates. Taking the example of 
PTx; although we had a very small effect size of -0.1, the bootstrapped confidence interval ranged 
from -0.78 to 0.66, prohibiting our ability to definitively conclude that there is no difference 
between the vaccinated and unvaccinated groups. We believe that our study provides useful data 
for power calculations of future longitudinal mother-infant cohort studies, including the 
measurement of antibodies against a range of different vaccines (Tdap/DTaP, pneuomoccocal and 
Hib), antibody half-life, vaccine interference and the impact of gestation at vaccination. 
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The UK vaccination schedule at the time of the study meant that both women (Repevax® or Boostrix-
IPV®) and infants (Pediacel® or Infanrix-IPV-Hib®) received one of two vaccines with different 
antigenic composition. The multiplex assay did not measure FIM antibody contained in both 
Repevax® and Pediacel®. Feunou-Feunou et al. (2016) demonstrated in mice that there is the 
potential for greater interference of maternal antibody when mother-infants pairs receive vaccines 
from the same manufacturer.39 We were unable to carry out this type of analysis given that the 
majority of women in our study (14/16) were vaccinated with Boostrix-IPV® that does not contain 
FIM antigen. There is a clinical trial in the UK to compare antibody levels following vaccination with 
different vaccines (ClinicalTrials.gov identifier NCT02145624) that could shed further light on these 
observations from the mouse model.  
 
Conclusions 
In the UK, maternal pertussis vaccination during pregnancy protects infants during the critical first 
weeks of life before commencement of pediatric vaccination, confirming underlying principles for 
protection of vulnerable newborns against vaccine-preventable infections via maternal 
immunisation. In this small study, we found that maternal Tdap-vaccination results in robust 
antibody concentrations in infants during their critical first weeks of life, before they receive primary 
immunisation. Future studies should include investigation of the optimal gestation at which to 
vaccinate pregnant women to maximise high vaccine coverage and protection of infants.  
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Figure Legends 
Figure 1. Anti-Tdap antibody concentrations in mothers and their infants from Tdap-vaccinated 
and -unvaccinated pregnancies (A-E). The proportion of infants from Tdap-vaccinated and -
unvaccinated pregnancies reaching antibody thresholds (F-J). A-E: Anti-Tdap IgG were quantified in 
mother-infant pairs from vaccinated (white circle) and unvaccinated (black circle) pregnancies. Data 
were log-transformed, and a random effects model applied. Mean and 95% confidence intervals are 
shown. The vaccinated group had significantly elevated antibody to A) PTx B) FHA C) Prn D) Dtx and 
E) TTx vaccine antigens in mothers at birth, in cord blood and in the infant pre-vaccination. Post-
infant vaccination, there were no significant differences in antibody to any of the vaccine antigens 
between vaccinated and unvaccinated groups (* = p<0.05; *** = p<0.001; **** = p<0.0001; 
unvaccinated n=15; vaccinated n=16). F-J: Cut-offs were set at ≥20IU/ml for pertussis antigens, and 
≥0.1 IU/mL for DTx and TTx. The proportion of infants at birth, 7 weeks and 5 months that reached 
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these cut-offs is represented as a percentage of total samples analysed in vaccinated (solid line) and 
unvaccinated (dashed line) groups. At birth and 7 weeks, the percentage of infants reaching 
seropositive levels for PTx, FHA, Prn and DTx was significantly higher in the group born to Tdap-
vaccinated mothers than those born to non-vaccinated mothers. There was no difference for TTx. 
Post-primary immunisation, there was no difference between the two groups. (** p<0.01; *** 
p<0.001; **** p<0.0001). 
Table 1. Active transfer of Tdap vaccine-specific antibodies from mother to infant. Mean 
fetal/maternal antibody ratios and 95% confidence intervals for IgG against Tdap antigens PTx, FHA, 
Prn, DTx and TTx. 
Table 2. Half-life of Tdap-specific maternal antibody between birth and seven weeks. Mean half-life 
of in days and 95% confidence intervals for maternal IgG against Tdap antigens PTx, FHA, Prn, DTx 
and TTx. 
Figure 2. Longitudinal pneumococcal and Hib antibody concentrations in mothers and their infants 
from maternal Tdap vaccinated and unvaccinated pregnancies. IgG against pneumococcal 
serotypes (Ps) and Haemophilus influenzae (Hib) were quantified in mother-infant pairs from 
vaccinated (white circles) and unvaccinated (black circles) pregnancies. Data was log transformed, 
and a random effects model applied. Mean and 95% confidence intervals are shown. No differences 
were observed in antibody to serotypes A) 1 B) 4 C) 5 D) 6B E) 7F F) 9V G) 14 H) 18C I) 19F J) 23F in 
mothers during pregnancy and at birth, or in cord blood and the infant pre-vaccination. Post-
vaccination, infants from vaccinated pregnancies had elevated serotype 14, whereas infants from 
the unvaccinated group had elevated 7F. K) Hib antibody did not differ between vaccinated and 
unvaccinated groups at any study time points (* p<0.05; ** p<0.01; unvaccinated n=15; vaccinated 
n=16). 
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Supplementary figure 1. Participant flow diagram. 
Supplementary table 1. Demographic data of the MatImms study population included for analysis. 
Data represents mean values unless stated otherwise, and 95% confidence intervals in parentheses. 
(NS = not significant; N/A = not applicable). 
Supplementary table 2. Antibody levels against acellular pertussis antigens, Haemophilus 
influenzae type b and Streptococcus pneumoniae.  Untransformed data showing the mean antibody 
concentrations (IU/ml for PTx, FHA, Prn, DTx and TTx; µg/ml for Hib and pneumococcal antigens) of 
all measured antigen-specific IgG, at the five study timepoints in vaccinated and unvaccinated 
groups. 95% confidence intervals in parentheses, p values derived from analysis of log-transformed 
data.  
 
 
Fetal/Maternal IgG ratios (CI) – IU/ml 
Vaccine Antigen Unvaccinated Vaccinated p value 
PTx 2.28 (1.16-3.41) 2.16 (1.80-2.53) 0.41 
FHA 2.23 (1.53-2.93) 2.15 (1.79-2.51) 0.62 
Prn 2.33 (1.07-3.60) 2.14 (1.79-2.69) 0.08 
DTx 1.64 (1.42-1.87) 2.10 (1.76-2.46) 0.04 
TTx 1.58 (1.35-1.81) 2.07 (1.76-2.39) 0.03 
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IgG half-life in infants, in days (CI) – IU/ml 
Vaccine Antigen Unvaccinated Vaccinated p value 
PTx 27.2 (20.0-42.3) 28.9 (26.9-31.3) 0.65 
FHA 25.0 (19.5-34.7) 29.7 (27.7-32.1) 0.72 
Prn 26.1 (18.5-44.4) 28.1 (25.4-31.3) 0.47 
DTx 21.8 (18.2-27.2) 26.1 (24.5-27.9) 0.16 
TTx 26.6 (19.3-42.6) 29.5 (26.8-32.8) 0.62 
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